These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23185925)

  • 21. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 22. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 24. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial.
    Sadeghi M; Hoseini SG; Nateghi A; Sarrafzadegan N; Mansoorian M; Najafian J; Roohafza H
    Curr Probl Cardiol; 2022 Jun; 47(6):100872. PubMed ID: 34016484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polypill strategy for primary prevention of cardiovascular disorders.
    Dabhadkar KC; Bellam N
    Drugs Today (Barc); 2013 May; 49(5):317-24. PubMed ID: 23724411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
    Green LW
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uses of polypills for cardiovascular disease and evidence to date.
    Huffman MD; Xavier D; Perel P
    Lancet; 2017 Mar; 389(10073):1055-1065. PubMed ID: 28290995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for a cardiovascular disease prevention polypill.
    Dabhadkar KC; Kulshreshtha A; Ali MK; Narayan KM
    Annu Rev Public Health; 2011; 32():23-38. PubMed ID: 21219156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 30. The challenge of polypharmacy in cardiovascular medicine.
    Volpe M; Chin D; Paneni F
    Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
    Frishman WH; Zuckerman AL
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):675-81. PubMed ID: 15350169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention - the HIV polypill study.
    Law MG
    Curr Opin HIV AIDS; 2006 Nov; 1(6):482-7. PubMed ID: 19372850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
    Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
    J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polypill in cardiovascular disease: has it's time come?
    Kuppuswamy V; Choo WK; Gupta S
    Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
    [No Abstract]   [Full Text] [Related]  

  • 35. [Primary prevention of cardiovascular diseases with statins in women].
    Alici G; Karpuz V; Karpuz H
    Turk Kardiyol Dern Ars; 2009 Jun; 37(4):273-80. PubMed ID: 19717964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
    Ibraheem M; Goldstein LB
    Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
    Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
    Franco OH; Karnik K; Bonneux L
    Horm Metab Res; 2007 Sep; 39(9):627-31. PubMed ID: 17846968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cut stroke in half: Polypill for primary prevention in stroke.
    Brainin M; Feigin V; Martins S; Matz K; Roy J; Sandercock P; Teuschl Y; Tuomilehto J; Wiseman A
    Int J Stroke; 2018 Aug; 13(6):633-647. PubMed ID: 29461155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.